Disc Medicine Inc

IRON

Company Profile

  • Business description

    Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

  • Contact

    321 Arsenal Street
    Suite 101
    WatertownMA02472
    USA

    T: +1 617 674-9274

    https://www.discmedicine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    155

Stocks News & Analysis

stocks

Fears of deteriorating loan quality sends bank share plummeting

We maintain our fair value estimate despite unfavourable economic conditions.
stocks

Why it’s not all bad news for Flight Centre following downgrade

Despite an earnings downgrade, shares in FLT remain undervalued.
stocks

Chart of the Week: What 650 IPOs reveal about long-term performance

Our data shows buying into the IPO hype can be costly.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,964.201.20-0.01%
CAC 408,384.8746.74-0.55%
DAX 4024,671.22323.61-1.29%
Dow JONES (US)51,876.1144.51-0.09%
FTSE 10010,508.0221.87-0.21%
HKSE22,671.86405.05-1.76%
NASDAQ25,297.6260.99-0.24%
Nikkei 22569,360.883,005.46-4.15%
NZX 50 Index13,495.242.190.02%
S&P 5007,354.023.47-0.05%
S&P/ASX 2008,764.200.200.00%
SSE Composite Index4,027.2693.02-2.26%

Market Movers